Melanotan II Side Effects

Known side effects

The following side effects have been reported in research studies and user reports for Melanotan II:

• Nausea and vomiting: The most common side effect, dose-dependent, occurring in up to 12.9% of subjects at 0.025 mg/kg. Typically most severe during initial loading phase. Community mitigation strategies include injecting before bedtime, starting at 100-250 mcg, and eating a light meal beforehand (PMID: 11035391).
• Facial flushing: Common warmth and redness appearing within minutes of injection, usually resolving within 1-2 hours. More pronounced at higher doses and in fair-skinned individuals. Reduces with continued use.
• Spontaneous penile erections: Documented in the Phase I trial and subsequent studies. Erections may occur 1-5 hours post-injection without sexual stimulation. Can be socially disruptive and, in rare cases, may progress to priapism requiring emergency medical intervention (PMID: 8637402, 9679884).
• New mole formation and darkening of existing moles: One of the most consistently reported dermatological effects. MT-II stimulates melanocytes broadly, causing darkening of existing nevi, emergence of new nevi, and development of atypical melanocytic lesions. Some changes may persist permanently after cessation (PMID: 28266027).
• Freckle darkening and uneven pigmentation: MT-II can intensify existing freckles, make previously invisible freckles apparent, and produce uneven pigmentation in areas with higher melanocyte density (face, armpits, genital area). Fair-skinned individuals are most affected.
• Appetite suppression and decreased appetite: Reported in clinical trials as an incidental effect alongside tanning and sexual function outcomes. May be more pronounced during initial dosing and typically attenuates with continued use (PMID: 9679884).
• Fatigue and somnolence: Reported in the original Phase I trial. Some users experience drowsiness following injection, which contributed to the community practice of evening administration (PMID: 8637402).
• Headache: Reported across multiple clinical trials at varying rates. Usually mild and self-limiting.
• Rhabdomyolysis (rare, dose-dependent): Severe skeletal muscle breakdown documented in a case report involving a 6x overdose (6 mg instead of recommended starting dose). CPK peaked at 17,773 IU/L with associated renal dysfunction. Required 3-day ICU admission (PMID: 23121206). Risk appears strongly dose-dependent and associated with unregulated product use.
• Renal infarction and kidney damage (rare): Case report documented disruption of kidney blood flow attributed to MT-II use, with proposed mechanisms including thrombotic effects and direct renal parenchymal toxicity (PMID: 31953620).
• Melanoma risk (uncertain causation): Four documented melanoma cases in MT-II users reported in a 2017 review (PMID: 28266027). One case involved a 20-year-old with no prior risk factors (PMID: 24355990). A 2025 case report documented oral mucosal melanoma in a 22-year-old MT-II nasal spray user — significant because oral mucosa is not UV-exposed, suggesting risk may exist independent of UV-seeking behavior. Causation remains unproven, but both increased UV-seeking behavior and direct melanocyte overstimulation are plausible contributing mechanisms.
• Elevated blood pressure: Transient cardiovascular effects including blood pressure increases were among the safety concerns that led to the halt of pharmaceutical development around 2003. Monitor blood pressure during use.
• Product quality and contamination risk: Unregulated MT-II products purchased online have been found to contain 4-6% impurities. Since no pharmaceutical-grade MT-II is available for non-research use, product quality is inherently uncertain. Risks include bacterial endotoxin contamination, incorrect peptide sequences, and degradation products.
• Yawning and stretching: Unusual but repeatedly documented effect in clinical trials, believed to be centrally mediated through melanocortin receptor activation in the brainstem (PMID: 8637402). Generally not clinically significant but can be noticeable.

Severity and frequency

Limited clinical data is available for Melanotan II. Side effect frequency and severity are based on available research and anecdotal reports. More data is needed for definitive safety profiles.

When to seek medical attention

Contact your healthcare provider immediately if you experience:

• Severe or persistent symptoms that do not improve
• Signs of an allergic reaction (rash, swelling, difficulty breathing)
• Severe abdominal pain
• Changes in vision or neurological symptoms
• Any symptom that concerns you

Risk factors

Side effect risk may be higher in certain populations. Discuss your complete medical history with your doctor, including:

• Pre-existing medical conditions
• Current medications (drug interactions)
• Pregnancy or plans to become pregnant
• History of allergic reactions to peptides or similar compounds
• Note: Melanotan II is a research compound without established human safety data from FDA-approved clinical trials

Research references

• Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study — Life Sciences (1996) [PubMed]
• Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers — Archives of Dermatology (2004) [PubMed]
• Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study — Journal of Urology (1998) [PubMed]
• Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II — International Journal of Impotence Research (2000) [PubMed]
• Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction — Urology (2000) [PubMed]
• Discovery that a melanocortin regulates sexual functions in male and female humans — Peptides (2005) [PubMed]
• Use of melanotan I and II in the general population — BMJ (2009) [PubMed]
• Intermittent MTII application evokes repeated anorexia and robust fat and weight loss — Peptides (2010) [PubMed]
• Activation of the central melanocortin system chronically reduces body mass without the necessity of long-term caloric restriction — Canadian Journal of Physiology and Pharmacology (2017) [PubMed]
• Melanotan II injection resulting in systemic toxicity and rhabdomyolysis — Clinical Toxicology (2012) [PubMed]
• Melanotan II: a possible cause of renal infarction: review of the literature and case report — CEN Case Reports (2020) [PubMed]
• Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review — International Journal of Dermatology (2017) [PubMed]
• Melanoma associated with the use of melanotan-II — Dermatology (2014) [PubMed]
• Afamelanotide for Erythropoietic Protoporphyria — New England Journal of Medicine (2015) [PubMed]
• Increased phototoxic burn tolerance time and quality of life in patients with erythropoietic protoporphyria treated with afamelanotide - a three years observational study — Orphanet Journal of Rare Diseases (2020) [PubMed]